Companies
From start-ups to market leaders, access critical company intelligence on a global scale
Experience what our solutions have to offer with free access to highlights of our data, insights and analysis.
From start-ups to market leaders, access critical company intelligence on a global scale
From industry deep dives to global trends, access authoritative research from our experts
Uncover your next opportunity with trusted data & insights that cut across industries
Discover the disruptive forces shaping tomorrow's world, today
Explore our diverse collection of unique datasets and find the advantage you need
Get clarity into the latest emerging themes with our reports
Experience what our solutions have to offer with free access to highlights of our data, insights and analysis.
From start-ups to market leaders, access critical company intelligence on a global scale
From industry deep dives to global trends, access authoritative research from our experts
Uncover your next opportunity with trusted data & insights that cut across industries
Discover the disruptive forces shaping tomorrow's world, today
Explore our diverse collection of unique datasets and find the advantage you need
Get clarity into the latest emerging themes with our reports
There is an agreement among KOLs in the 7MM that supportive oncology has not been prioritised by physicians and institutions in the past.
This has been improving in recent years with the increasing appreciation of the importance of supportive care. Supportive care in oncology is a broad term composed of indications that are either a symptom of a patient’s cancer or a side effect of cancer treatment. This report focuses on six prominent cancer supportive care indications: chemotherapy-induced nausea and vomiting (CINV), cancer cachexia, oral mucositis, bone metastases, chemotherapy-induced neutropenia (CIN), and chemotherapy-induced anemia (CIA). This report is part of our Biosimilars market series.
Traditionally an overlooked field, supportive oncology is growing across the 7MM (US, France, Germany, Italy, Spain, UK and Japan) and this growth will continue in the next 5-10 years.
Evidence suggests that supportive care increases the likelihood of finishing treatment, without the need for dose reductions or pauses in treatment. It can also reduce costs for healthcare institutions and improve quality of life for patients—all of which will become increasingly important as patients continue to live longer, and cancer becomes more like a chronic disease.
Despite oncology trends towards targeted therapies and new modalities of treatment such as immunotherapies, KOLs agree that chemotherapy will remain the backbone of cancer treatment for the next 5-10 years. Therefore, as the incidence of cancer rises, so will cases of chemotherapy-related conditions, in addition to a rise in general oncology-related conditions.